+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Insulin-Like Growth Factor Binding Protein Market by Application (Diagnostics, Research Reagents, Therapeutics), Product Type (IGFBP-1, IGFBP-2, IGFBP-3), Technology, End User - Global Forecast 2025-2030- Product Image
Insulin-Like Growth Factor Binding Protein Market by Application (Diagnostics, Research Reagents, Therapeutics), Product Type (IGFBP-1, IGFBP-2, IGFBP-3), Technology, End User - Global Forecast 2025-2030- Product Image
New

Insulin-Like Growth Factor Binding Protein Market by Application (Diagnostics, Research Reagents, Therapeutics), Product Type (IGFBP-1, IGFBP-2, IGFBP-3), Technology, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6142730
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Insulin-like growth factor binding proteins (IGFBPs) play an indispensable role in modulating the bioavailability and activity of insulin-like growth factors, which are central to cellular proliferation, differentiation, and survival. These binding proteins not only regulate hormone activity in physiological processes such as growth and metabolism, but they also offer valuable biomarkers for clinical diagnostics and targets for novel therapeutic approaches. Recent advances have further revealed how distinct IGFBP isoforms interact with receptors and extracellular matrix components, underscoring their multifaceted contributions to health and disease.

As research applications evolve from basic science investigations to precision medicine, interest in IGFBPs has surged across diagnostic laboratories, pharmaceutical companies, and academic institutes. Technological improvements in assay sensitivity and specificity have accelerated translational studies, enabling more robust disease stratification and personalized treatment strategies. In the wake of these developments, this executive summary offers a comprehensive overview of current market dynamics, emerging trends, and strategic considerations for stakeholders looking to leverage the full potential of IGFBPs in diagnostics, research reagents, and therapeutics.

Charting the Impact of Technological Innovations, Regulatory Changes, and Therapeutic Advances Reshaping the Growth Factor Binding Protein Landscape

The insulin-like growth factor binding protein landscape has been reshaped by a convergence of technological breakthroughs, evolving regulatory frameworks, and novel therapeutic paradigms. Cutting-edge assay platforms, such as high-throughput sandwich ELISA formats and mass spectrometry-based proteomic profiling, have delivered unprecedented resolution in quantifying IGFBP isoforms. Simultaneously, advances in immunohistochemistry protocols allow for precise spatial mapping of IGFBP expression within tissue microenvironments, enriching our understanding of disease pathology.

On the regulatory front, updated guidelines for companion diagnostic validation have accelerated the path to market for IGFBP-based assays, while enhanced clarity on biomarker qualification has given biopharmaceutical developers greater confidence in incorporating these proteins into clinical trials. In parallel, therapeutic innovation has extended beyond growth disorder management into oncology and metabolic disease, with several pipeline candidates targeting IGFBP interactions to modulate tumor progression and insulin sensitivity. Together, these transformative shifts form the foundation for a dynamic and growth-oriented IGFBP ecosystem.

Analyzing the Effects of United States 2025 Tariffs on Supply Chains, Pricing Dynamics, and Strategic Positioning in the IGFBP Sector

In 2025, the United States introduced new tariffs on imported biochemical reagents and recombinant proteins, including those essential for IGFBP assay production. These measures have introduced additional cost pressure on suppliers of plasma-derived binding proteins and recombinant IGFBP-3, prompting contract manufacturers to reassess sourcing strategies. Consequently, organizations have accelerated efforts to qualify domestic production partners, while some have actively explored nearshoring options in neighboring regions to mitigate the impact of increased duties.

Pricing dynamics have also adjusted, with distributors reallocating premiums across clinical and research reagent portfolios to cover higher input costs. This has led to strategic renegotiations between reagent manufacturers and end users, particularly among diagnostic laboratories that rely on tight budgetary controls. Meanwhile, manufacturers of advanced instrumentation have taken advantage of the supply chain recalibration to bundle assay kits with analytical platforms, reinforcing long-term service agreements and preserving market share in an environment of shifting trade policies.

Uncovering Critical Segmentation Insights That Illuminate Diverse Applications, Product Types, Technological Modalities, and End User Dynamics in the IGFBP Market

A nuanced understanding of market segmentation reveals distinct growth pathways for IGFBPs across multiple dimensions. From an application standpoint, clinical diagnostics continues to expand as laboratories adopt sensitive assays for patient stratification, while companion diagnostics for targeted therapies gain traction. Meanwhile, preclinical diagnostics remain critical for translational studies, and research reagents such as monoclonal antibodies, assay kits, and recombinant proteins serve as the backbone of academic and biotech discovery endeavors. In parallel, the therapeutic segment addresses cancer therapy, growth disorders, and metabolic diseases, each with unique demands on binding protein formulations and delivery mechanisms.

Examining product types underscores the leadership of IGFBP-3, available in both plasma-derived and recombinant forms, given its central role in apoptosis and cell growth regulation. Equally important are other family members, from IGFBP-1 through IGFBP-7, each presenting differentiated biological profiles for niche applications. Technology segmentation further refines market insight: competitive, direct, and sandwich ELISA formats drive high-throughput quantitative analyses, while immunohistochemistry offers spatial context in tissue samples. Mass spectrometry and western blotting remain essential for qualitative validation and post-translational modification studies. Finally, end users comprising academic institutes, diagnostic laboratories, pharmaceutical companies, and dedicated research centers exhibit varied procurement priorities, with academic and research entities prioritizing versatility and cost efficiency, and diagnostic and pharmaceutical organizations emphasizing regulatory compliance and scalability.

Revealing Strategic Regional Variations and Market Drivers That Shape the Dynamics of IGFBP Across the Americas, EMEA, and Asia-Pacific

Regional dynamics in the IGFBP market are shaped by distinct scientific, regulatory, and commercial drivers. In the Americas, robust funding for academic research and a rapid adoption of companion diagnostics underpin steady demand for high-performance assay platforms. Leading pharmaceutical hubs in North America continue to invest in next-generation IGFBP modulators, while contract research organizations expand service offerings in preclinical biomarker validation. These developments position the region as a central innovator in both reagent provision and therapeutic pipeline advancement.

Meanwhile, the Europe, Middle East & Africa region benefits from harmonized regulatory pathways and strong collaborations between public research institutes and biotech startups. The European Union’s streamlined approval processes for in vitro diagnostic devices have bolstered uptake of advanced IGFBP assays, particularly in oncology applications. In emerging markets across EMEA, growing healthcare infrastructure and increasing research grants are elevating the role of IGFBPs in clinical and preclinical settings. Transitioning to Asia-Pacific, the market exhibits rapid growth driven by escalating investments in personalized medicine, rising prevalence of metabolic disorders, and expanding manufacturing capabilities. Governments in key Asia-Pacific economies are incentivizing local production of critical reagents, thereby reinforcing supply chain resilience and amplifying regional competitiveness.

Examining Leading Industry Players Driving Innovation, Strategic Partnerships, and Competitive Dynamics in the IGFBP Market Ecosystem

The competitive landscape of the insulin-like growth factor binding protein market is characterized by a blend of global life science giants, specialized diagnostics firms, and emerging biotech innovators. Major players have leveraged their extensive commercial networks to distribute a comprehensive range of IGFBP assay kits and reagents, often bundling them with high-throughput analytical instrumentation. Simultaneously, specialized companies have carved out niches by focusing on ultra-sensitive binding protein detection or by licensing proprietary antibodies for targeted research applications.

Strategic alliances between reagent suppliers and pharmaceutical developers have accelerated co-development of companion diagnostic assays, while partnerships with academic centers have reinforced credibility and fostered early adoption. In addition, a wave of start-ups is charting new territory by engineering recombinant IGFBP analogs with enhanced stability and specificity, catering to novel therapeutic strategies in oncology and metabolic disease. Amid this dynamic ecosystem, ongoing investment in R&D and a clear focus on regulatory compliance will determine which organizations establish a sustainable competitive edge.

Actionable Strategies to Maximize Technological Advances, Navigate Regulatory Pathways, and Exploit Emerging Applications in the IGFBP Sector

To capitalize on current market opportunities, organizations should prioritize the development of high-sensitivity assay platforms that differentiate IGFBP isoforms, while streamlining validation protocols to meet evolving regulatory requirements. Engaging early with regulatory authorities to secure biomarker qualification for companion diagnostic applications can accelerate time to market and mitigate approval risks. Furthermore, diversifying supply chains through relationships with regional manufacturing partners will reduce exposure to tariff fluctuations and logistical disruptions.

In parallel, forging collaborations with academic institutes and research centers can enhance credibility and facilitate access to emerging clinical use cases. Strategic investments in recombinant protein engineering-aimed at improving binding stability or tissue specificity-will unlock new therapeutic indications. Finally, proactive exploration of high-growth regions, supported by tailored market entry strategies, will position organizations to capture unmet needs in diagnostic and therapeutic segments across the Americas, EMEA, and Asia-Pacific.

Outlining a Robust Mixed-Method Research Framework Combining Primary Expert Insights and Secondary Industry Analysis to Illuminate IGFBP Market Dynamics

This analysis combines primary and secondary research methodologies to deliver a comprehensive view of the IGFBP market. Primary research consisted of in-depth interviews with leading academic researchers, senior R&D executives in pharmaceutical companies, and heads of diagnostic laboratories. These discussions provided qualitative insights into technological adoption, unmet clinical needs, and evolving product specifications. To complement these perspectives, a broad review of peer-reviewed journals, patent filings, regulatory guidance documents, and industry white papers was conducted, ensuring that findings are grounded in the latest scientific and policy developments.

Quantitative data were gathered through proprietary surveys targeting reagent procurement managers and assay developers, enabling triangulation of pricing trends, procurement volumes, and technology preferences. All data underwent validation via cross-referencing with publicly available financial reports, trade statistics, and expert feedback to ensure accuracy and relevance. This mixed-method approach allowed for robust analysis of market dynamics, segmentation, competitive positioning, and growth drivers, culminating in a strategic roadmap for stakeholders.

Summarizing the Critical Findings and Future Outlook That Emphasize the Strategic Importance of IGFBP in Advancing Diagnostics, Research, and Therapeutics

The global insulin-like growth factor binding protein market stands at a pivotal juncture where scientific innovation, regulatory clarity, and emerging clinical applications converge to drive sustained growth. Recent advances in assay technologies and therapeutic modalities have deepened our understanding of IGFBP biology, reinforcing its significance across diagnostics, research, and treatment landscapes. Meanwhile, evolving trade policies and regional funding initiatives continue to reshape supply chain configurations and market access pathways.

Looking ahead, stakeholders who embrace advanced segmentation strategies, fortify their regulatory engagement, and leverage collaborative partnerships will be best positioned to capture the next wave of opportunities. As the IGFBP ecosystem evolves, strategic decision-makers must maintain agility, invest in R&D, and cultivate a data-driven approach to navigate the complexities of this dynamic market. Ultimately, a clear alignment of scientific innovation with commercial execution will define success in harnessing the full potential of insulin-like growth factor binding proteins.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Diagnostics
      • Clinical Diagnostics
      • Companion Diagnostics
      • Preclinical Diagnostics
    • Research Reagents
      • Antibodies
      • Assay Kits
      • Recombinant Proteins
    • Therapeutics
      • Cancer Therapy
      • Growth Disorders
      • Metabolic Disorders
  • Product Type
    • IGFBP-1
    • IGFBP-2
    • IGFBP-3
      • Plasma Derived
      • Recombinant
    • IGFBP-4
    • IGFBP-5
    • IGFBP-6
    • IGFBP-7
  • Technology
    • ELISA
      • Competitive ELISA
      • Direct ELISA
      • Sandwich ELISA
    • Immunohistochemistry
    • Mass Spectrometry
    • Western Blotting
  • End User
    • Academic Institutes
    • Diagnostic Laboratories
    • Pharmaceutical Companies
    • Research Centers
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Bio-Techne Corporation
  • Abcam plc
  • R&D Systems, Inc.
  • RayBiotech Life, Inc.
  • Cloud-Clone Corp.
  • Proteintech Group, Inc.
  • Boster Biological Technology Co., Ltd.
  • Elabscience Biotechnology Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of IGFBP-3 companion diagnostic assays in personalized cancer treatment strategies
5.2. Advancements in recombinant IGFBP formulation technologies for improved bioavailability and stability
5.3. Emergence of biosimilar IGFBP products driven by patent expirations and cost containment pressures
5.4. Growth opportunities in emerging markets driven by rising incidence of metabolic and growth disorders
5.5. Strategic collaborations between biopharma companies and academic centers for IGFBP research and development
5.6. Increased regulatory scrutiny on IGFBP therapeutic safety profiles influencing clinical trial designs
5.7. Application of machine learning algorithms in IGFBP target identification and drug discovery processes
5.8. Integration of patient-specific IGFBP level monitoring into chronic disease management protocols
5.9. Impact of healthcare reimbursement policies on market access for novel IGFBP-based therapeutics
5.10. Public-private partnerships accelerating IGFBP biomarker validation and assay commercialization pathways
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Insulin-Like Growth Factor Binding Protein Market, by Application
8.1. Introduction
8.2. Diagnostics
8.2.1. Clinical Diagnostics
8.2.2. Companion Diagnostics
8.2.3. Preclinical Diagnostics
8.3. Research Reagents
8.3.1. Antibodies
8.3.2. Assay Kits
8.3.3. Recombinant Proteins
8.4. Therapeutics
8.4.1. Cancer Therapy
8.4.2. Growth Disorders
8.4.3. Metabolic Disorders
9. Insulin-Like Growth Factor Binding Protein Market, by Product Type
9.1. Introduction
9.2. IGFBP-1
9.3. IGFBP-2
9.4. IGFBP-3
9.4.1. Plasma Derived
9.4.2. Recombinant
9.5. IGFBP-4
9.6. IGFBP-5
9.7. IGFBP-6
9.8. IGFBP-7
10. Insulin-Like Growth Factor Binding Protein Market, by Technology
10.1. Introduction
10.2. ELISA
10.2.1. Competitive ELISA
10.2.2. Direct ELISA
10.2.3. Sandwich ELISA
10.3. Immunohistochemistry
10.4. Mass Spectrometry
10.5. Western Blotting
11. Insulin-Like Growth Factor Binding Protein Market, by End User
11.1. Introduction
11.2. Academic Institutes
11.3. Diagnostic Laboratories
11.4. Pharmaceutical Companies
11.5. Research Centers
12. Americas Insulin-Like Growth Factor Binding Protein Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Insulin-Like Growth Factor Binding Protein Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Insulin-Like Growth Factor Binding Protein Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Thermo Fisher Scientific Inc.
15.3.2. Merck KGaA
15.3.3. Bio-Techne Corporation
15.3.4. Abcam plc
15.3.5. R&D Systems, Inc.
15.3.6. RayBiotech Life, Inc.
15.3.7. Cloud-Clone Corp.
15.3.8. Proteintech Group, Inc.
15.3.9. Boster Biological Technology Co., Ltd.
15.3.10. Elabscience Biotechnology Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET: RESEARCHAI
FIGURE 24. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET: RESEARCHSTATISTICS
FIGURE 25. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET: RESEARCHCONTACTS
FIGURE 26. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRECLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRECLINICAL DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY CANCER THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY CANCER THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-1, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-1, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-2, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-2, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-4, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-4, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-5, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-5, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-6, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-6, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-7, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-7, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIRECT ELISA, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIRECT ELISA, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 131. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 132. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 133. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 134. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 135. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 136. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 137. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 138. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 139. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 142. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 143. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 144. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 145. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 146. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 147. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. CANADA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 150. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 151. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 158. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 159. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 160. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 161. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 162. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 163. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 164. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 165. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. MEXICO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 242. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 243. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 246. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 247. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 248. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 249. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 252. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 253. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 254. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 255. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 256. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 257. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. GERMANY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 260. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 261. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 263. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2018-2024 (USD MILLION)
TABLE 264. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY RESEARCH REAGENTS, 2025-2030 (USD MILLION)
TABLE 265. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 266. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 267. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 268. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 269. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2018-2024 (USD MILLION)
TABLE 270. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY IGFBP-3, 2025-2030 (USD MILLION)
TABLE 271. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 272. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 273. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
TABLE 274. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY ELISA, 2025-2030 (USD MILLION)
TABLE 275. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. FRANCE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN MARKET SIZE, BY END

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Insulin-Like Growth Factor Binding Protein market report include:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Bio-Techne Corporation
  • Abcam plc
  • R&D Systems, Inc.
  • RayBiotech Life, Inc.
  • Cloud-Clone Corp.
  • Proteintech Group, Inc.
  • Boster Biological Technology Co., Ltd.
  • Elabscience Biotechnology Co., Ltd.

Related Topics

Related Reports

Insulin Resistance - Pipeline Insight, 2025 - Product Image

Insulin Resistance - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Pediatric Growth Hormone Deficiency - Pipeline Insight, 2025 - Product Image

Pediatric Growth Hormone Deficiency - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Insulin-like Growth Factors - Global Strategic Business Report - Product Image

Insulin-like Growth Factors - Global Strategic Business Report

  • Report
  • 270 Pages
  • Global
From
2024 Middle East Immunoassay Analyzers and Reagents in 11 Countries - Supplier Shares and Competitive Analysis, 2023-2028 Volume and Sales Segment Forecasts for 100 Abused Drugs, Cancer Diagnostic, Endocrine Function, Immunoproteins, TDMs, and Special Chemistry Tests - Product Image

2024 Middle East Immunoassay Analyzers and Reagents in 11 Countries - Supplier Shares and Competitive Analysis, 2023-2028 Volume and Sales Segment Forecasts for 100 Abused Drugs, Cancer Diagnostic, Endocrine Function, Immunoproteins, TDMs, and Special Chemistry Tests

  • Report
  • Middle East
From
2024 Latin America Immunoassay Analyzers and Reagents in 22 Countries - Supplier Shares and Competitive Analysis, 2023-2028 Volume and Sales Segment Forecasts for 100 Abused Drugs, Cancer Diagnostic, Endocrine Function, Immunoproteins, TDMs, and Special Chemistry Tests - Product Image

2024 Latin America Immunoassay Analyzers and Reagents in 22 Countries - Supplier Shares and Competitive Analysis, 2023-2028 Volume and Sales Segment Forecasts for 100 Abused Drugs, Cancer Diagnostic, Endocrine Function, Immunoproteins, TDMs, and Special Chemistry Tests

  • Report
  • Latin America
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.